Recurrent Stage III Ovarian Cancer in a BRCA1 Carrier Treated With Multiple Therapies
This ovarian cancer diagnosis at a glance
- Stage at diagnosis
- Stage III
- Biomarkers
- BRCA1 mutation
- Sex
- female
- Treatment
- surgery, chemotherapy, targeted therapy and clinical trial
- Outcome
- Setback / Progression
Treatment course, step by step
- She underwent optimal debulking surgery followed by 6 cycles of carboplatin and paclitaxel.
- A 2004 recurrence was retreated with the same chemotherapy for 4 cycles before neuropathy stopped treatment.
- She later received intraperitoneal cisplatin and topotecan on protocol, then carboplatin with pegylated liposomal doxorubicin followed by maintenance therapy.
- She entered a trial of veliparib and cyclophosphamide in 2010.
- Bevacizumab was started in late 2011 for slowly progressive hilar nodal disease.
What happened, in summary
A 47-year-old woman underwent optimal debulking surgery for Stage III high-grade papillary serous ovarian cancer in 2001, followed by 6 cycles of carboplatin and paclitaxel. Testing showed a BRCA1 mutation.
The cancer returned in late 2004. Retreatment with carboplatin and paclitaxel was stopped after 4 cycles because of sensory neuropathy. With recurrent disease in hepatic hilar lymph nodes, she later received intraperitoneal cisplatin and topotecan on a treatment protocol. Another recurrence in 2007 led to 3 cycles of carboplatin with pegylated liposomal doxorubicin followed by maintenance therapy.
When the CA-125 level rose and imaging continued to show disease, she entered a phase II trial of veliparib and cyclophosphamide in 2010. The trial was stopped in 2011 because of worsening thrombocytopenia. Her ovarian disease had remained stable during treatment but then showed slow progression. In December 2011, bevacizumab was started for the progressing hilar nodal disease. She also developed separate skin and oral squamous cell cancers during this period, which were treated independently.
Where this story comes from
This is a lay summary of an account first published by PMC / PubMed Central. Read the original in full
How we source and attribute stories Accuracy and limitations
Collections this story belongs to
- Stage 3 Ovarian Cancer 35 stories
- BRCA1 Mutation Ovarian Cancer 13 stories
- Bevacizumab for Ovarian Cancer 19 stories
These are lay summaries of published cancer stories, for information only. No two cancers behave the same way, and nothing here predicts your own diagnosis or replaces advice from your oncology team. Read the full disclaimer